NEPTUNE, N.J., Jan. 26 /PRNewswire/ -- Dr. Robert A. Vukovich, Chairman and Founder of InfaCare Pharmaceutical Corporation, and Mr. John R. Post, President and CEO of InfaCare, jointly announced today that E. Ronald Goldfuss will join the company as Chief Financial Officer effective February 1, 2005. InfaCare is a specialty pharmaceutical company focused on developing innovative therapies for neonates and older children. The company is based in Neptune, NJ.
The Board of Directors is pleased with this appointment," said Dr. Vukovich. "Ron's broad financial background as CFO with various start-up organizations, his fund-raising expertise and general operational experience make him an ideal individual to join InfaCare's management team. Together with John Post, President and CEO, and other senior managers, we now have the core leadership team in place to implement the business plans of our emerging specialty pharmaceutical company."
Mr. Goldfuss has served as Chief Financial Officer for several biomedical and technology organizations including Songbird Hearing Inc., CompuCyte Corporation, Vital Sciences Inc., and Spinnaker Software Corporation. He was instrumental in taking Spinnaker Software public and has considerable experience in raising equity and debt capital for private and public companies. He also has extensive experience in mergers and acquisitions, and in technology licensing.
Mr. Goldfuss received his AB in economics from Boston College and his MBA from the Wharton School, University of Pennsylvania. He earned his CPA while with Arthur Andersen & Co.
InfaCare Pharmaceutical Corporation is a privately held pharmaceutical company founded in 2001 by Dr. Robert A. Vukovich. The company is currently developing Stanate(R) for the treatment of hyperbilirubinemia (elevated bilirubin levels leading to jaundice and possible neurological damage) in neonates.
CONTACT: Nancy Bracken
Tel: (732) 938-5885
Fax: (732) 751-9056
InfaCare Pharmaceutical Corporation
CONTACT: Nancy Bracken, InfaCare Pharmaceutical Corporation,+1-732-938-5885, Fax: +1-732-751-9056